Deloitte Expands Award-Winning Analytics Suite on Amazon Web Services to Support End-to-End Evidence Management has been added to your bookmarks.
Deloitte Expands Award-Winning Analytics Suite on Amazon Web Services to Support End-to-End Evidence Management
ConvergeHEALTH Miner enables life sciences companies to thrive in a value-based, personalized medicine paradigm
LAS VEGAS, Nov. 27, 2017 — Deloitte announced the expanded use of Amazon Web Services (AWS) for the award winning ConvergeHEALTH Miner product, adding AWS CloudFormation, Amazon Redshift, AWS Glue and AWS Lambda to expand its cloud-based solution for end-to-end evidence management for the life sciences industry.
Deloitte’s 2017 Real World Evidence Benchmarking Survey found evidence management as a top priority for the industry driven by the shift to value-based, personalized health care. Greater than 90 percent of life sciences companies surveyed are seeking knowledge management solutions that will enable broad sharing of information around the organization about studies conducted, evidence generated and data available. Further, 60 percent indicated that they were planning on using the cloud for analytics to enable these initiatives in a secure and scalable way, as well as to take advantage of the fast-paced data science and machine learning innovation happening in the cloud.
Deloitte’s ConvergeHEALTH Miner suite provides a flexible solution built on AWS, which enables clients to analyze data and to generate insights across the entire pharmaceutical value chain inclusive of translational research, clinical trials, real-world evidence, safety, market access and commercial products. Pharmaceutical companies are using the ConvergeHEALTH Miner suite, supported by new operating models and external data partnership strategies, to break down the traditional internal silos of evidence generation and think about an end-to-end evidence management strategy.
“In order to discover, optimize and demonstrate the value of real-world evidence, life sciences companies are embracing new strategies, innovative external partnerships, new operating models and innovative technology solutions,” said Brett J. Davis, principal, Deloitte Consulting LLP and general manager of ConvergeHEALTH by Deloitte. “Deloitte’s ConvergeHEALTH Miner suite on AWS is a solution that helps to break down the siloes for life sciences companies to thrive in a value-based, personalized medicine paradigm.”
Recently, Celgene won the Cloudera Cloud Pioneer Data Impact Award for its use of the ConvergeHEALTH Miner solution on Cloudera and AWS to support its big data and real-world evidence initiatives. “It’s a shift toward value-based and personalized care. There’s a real need to better understand both the profiles of our medicines and the patients who are going to benefit from them—as early in the drug discovery process as possible,” said Patrick Loerch, senior director of data science at Celgene. “With the ConvergeHEALTH Miner functionality, we now have a catalog of all available data – both internal datasets as well as external datasets that we have access to through our partnerships.”
With these new integrations, Deloitte is continuing its investment in a cloud-based approach to evidence management. Deloitte has added automated platform deployment of the ConvergeHEALTH Miner product leveraging AWS CloudFormation. For many users, this has significantly reduced deployment time. The Cohort Insight and Research Trust modules extend support to Amazon Redshift, a fast, fully managed data warehouse service. Additionally, ConvergeHEALTH Miner has integrated a new data lake catalog and management accelerator built on top of AWS Glue. The product now supports an advanced analytics library built on the AWS Lambda and Amazon Machine Learning (Amazon ML).
“Many biopharmaceutical companies are using real-world evidence platforms on AWS to derive new insights from their many disparate datasets,” said Aaron Friedman, Ph.D., partner solutions architect, AWS Partner Network, Amazon Web Services, Inc. “Solutions like the Deloitte ConvergeHEALTH solution, built on AWS, are already helping a wide variety of life sciences customers gain new knowledge from their datasets and advance human health.”
At AWS re:Invent 2017 these capabilities will be on display at several sessions:
- Nov. 27, Life Sciences Pre-Day: Dan Housman, consulting managing director and CTO of ConvergeHEALTH at Deloitte Consulting LLP and Patrick Loerch, senior director of data science at Celgene, will discuss the ConvergeHEALTH Miner suite on AWS in more detail and provide a case study of how it is being leveraged at Celgene.
- Nov. 28, Global Partner Summit: Dan Housman will join Oxana Pickeral, Ph.D., global segment lead, AWS Partner Network, Amazon Web Services, Inc., to discuss the convergence of factors facing life sciences innovators and how Deloitte is helping customers using AWS.
- Nov. 28, 11:30 a.m. PT, “Accelerating the Speed of Innovation with a Data Sciences Data & Analytics Hub at Takeda,” Ramin Darron, senior director at Takeda, Raveen Sharma, specialist leader at Deloitte Consulting LLP and Temi Adebambo of Deloitte Advisory.
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including more than 85 percent of the Fortune 500 and more than 6,000 private and middle market companies. Our people work across more than 20 industry sectors to make an impact that matters—delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthy society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them.